Ignite Creation Date:
2024-05-06 @ 8:15 PM
Last Modification Date:
2024-10-26 @ 3:23 PM
Study NCT ID:
NCT06305390
Status:
RECRUITING
Last Update Posted:
2024-04-12
First Post:
2024-03-05
Brief Title:
Fully Hybrid 18F-PSMA PETMRI as One-stop Approach for the Diagnosis of Clinically Significant Prostate Cancer
Sponsor:
IRCCS San Raffaele
Organization:
IRCCS San Raffaele
Study Overview
Official Title:
Fully Hybrid 18F-PSMA PETMRI as One-stop Approach for the Diagnosis of Clinically Significant Prostate Cancer
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
RF2021-1237227
Brief Summary:
This project aims to evaluate the role of fully hybrid PETMRI with 18FPSMA and multiparametric MR imaging mpMRI as one-stop approach for the diagnosis of clinically significant prostate cancer csPCa
Our main hypothesis is that adding 18F-PSMA PET to mpMRI prior to biopsy will reduce the number of false negative findings while at the same time allowing also to reduce the number of unnecessary prostate biopsies in patients with low-risk clinically indolent PCa
Our main hypothesis is that adding 18F-PSMA PET to mpMRI prior to biopsy will reduce the number of false negative findings while at the same time allowing also to reduce the number of unnecessary prostate biopsies in patients with low-risk clinically indolent PCa
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None